Skip to content

Data Migration and Mapping Functions

Data Migration and Mapping Functions

Medical software does not have a good reputation for user experience and intuitive design. It can seem like a full-time job just learning how to use these software solutions.  In fact, according to a study from Stanford Medicine, 74% of doctors responded that their EMR increased the number of hours they work every day and 71% say their EMRs lead to physician burnout.  With this information, coupled with the increase use of telehealth (another software to learn), it’s no wonder that providers and their staff are looking for alternatives to simplify their clinical software, while not sacrificing the quality of patient care.

At Arfinn Med, we believe that your clinical software should be easy to use, fast and allow you to spend more time focusing on patient care rather than data entry. This focus on intuitive software design is why we are the leading EMR for alternative medicine clinics including practices focusing on cannabis and cannabinoid medicine.  Despite this, we still hear from providers who wish to switch to our platform that they are concerned about migrating data from paper charts or from another system.  We at Arfinn Med decided to address this concern.

We are proud to release our new secure data mapping software and a team of employees to focus on data migration.  This new system will allow us to speed up the time it takes to switch patient data, while also not interrupting your current practice workflows. You will also be assigned a team member from Arfinn to help with extraction of any additional data such as attached files, appointments and/or consents.

If you are interested in learning more about our data migration protocol, please reach out to us at info@arfinnmed.com.

Sincerely from quarantine,

The Arfinn Med Team

Stories you may be interested in

Arfinn Med Patient Site

We get a lot of interest from patients asking about efficacy data for medical marijuana on a number of conditions. Though we are primarily an electronic medical record (EMR) company focussing on the cannabis industry and other complimentary or alternative therapies, our primary focus is better quality care for patients. So with that being said,…
Read More

Thanks to the Farm Bill, Hemp Is Legal. Here’s What It Means for CBD.

On Tuesday, the Senate voted to approve a new an $867 billion farm bill, and on Wednesday, it passed in Congress. While the bill has plenty of positive merits, the one people are perhaps most excited about is the fact that it will legalize the production, sale, and distribution of industrial hemp at a federal…
Read More

A Message To Our Clients

To Our Clients, First of all, I hope everyone is staying safe and healthy in these unprecedented times.  I want to assure you that Arfinn Med has systems in place to ensure that our workflows are not impacted from having staff work remotely and we will continue to provide the same quality product and customer service…
Read More

An Alternative Treatment for Parkinson’s Patients

April is Parkinson’s Awareness Month and an opportune time to highlight the disease and how medical marijuana may be a beneficial treatment option for those living with the condition. Many Parkinson’s patients find themselves desperate for alternative treatment options that provide sufficient relief of their symptoms and help avoid or postpone the need for surgery…
Read More

Substance in cannabis ‘could boost pancreatic cancer treatments’

A substance found in cannabis plants might boost treatments for patients with pancreatic cancer, research in mice has suggested. Cannabidiol, or CBD, is not psychoactive, meaning it does not produce feelings of being high in those who take it. It is extracted from hemp plants and is legal in the UK, although a CBD product…
Read More

Colorado’s first licensed cannabis R&D firm to study marijuana’s effect on Alzheimer’s disease

A Denver-based company hopes to be the state’s first to study the effects of marijuana on Alzheimer’s disease, thanks to a newly available research and development license in the city. MedPharm Holdings plans to apply for a Denver marijuana R&D license to test delta-9 tetrahydrocannabinol (THC), cannabidiol (CBD) and other cannabinoids’ effects on Alzheimer’s and…
Read More

Leave a Comment

You must be logged in to post a comment.